A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that leads to progressive muscle degeneration and weakness. Givinostat, an oral histone deacetylase inhibitor, was approved by the FDA in March 2024 for treatment of DMD in patients aged 6 years and older, regardless of mutation type.

Study participation will not influence the course of treatment in any way (including other treatments for DMD), and no treatment will be provided as part of this study. All assessments are intended to be performed at the time of a routine clinical care visit according to clinical practice, and data will be extracted from the medical records.

The FDA is requiring a post-marketing prospective study be conducted for a minimum of 5 years to characterize the incidence, frequency, and severity of thrombocytopenia and serious events of bleeding in patients with DMD treated with oral givinostat in routine clinical practice.

This study is designed as a prospective, observational study to assess safety (including evaluation of AEs of special interest \[AESIs\]) and effectiveness, in patients with DMD newly initiating oral givinostat as part of routine clinical care in the US in a real-world population. The study will assess AESIs noted above, as well as serious adverse events (SAEs), gastrointestinal (GI) AEs, and dehydration as a sequela to GI AEs. Real-world-treatment patterns of DMD treatments (corticosteroids, exon skipping oligonucleotides and gene therapy) prior to and after givinostat initiation, including treatment duration, and treatment combinations, will be described. Effectiveness evaluations will characterize motor function, quality of life, and activities of daily living in DMD patients treated with givinostat.

The study will enroll 300 participants (180 non-ambulatory and up to 120 ambulatory patients). Participants will be followed for at least two years, with data collected during routine clinical visits. Assessments include lab parameters (e.g., platelet counts, triglycerides), cardiac and pulmonary function, patient-reported outcomes, and motor function scales such as the North Star Ambulatory Assessment (NSAA) and Performance of Upper Limb (PUL) scale.

• Characterize the incidence of other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterize the frequency other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterize the severity of other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterize the incidence of all serious adverse events (SAEs) in DMD patients treated with oral givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterize the frequency of all serious adverse events (SAEs) in DMD patients treated with oral givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterize the incidence of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterize the frequency of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterize the severity of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat [Срок оценки: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
• Characterization of hematology laboratory parameters [Срок оценки: From baseline through end of study (up to 5 years)]
• Characterization of triglyceride laboratory parameters [Срок оценки: From baseline through end of study (up to 5 years)]